The in vitro Effect of Doxorubicine-G2-FA Treatment on Breast Cancer Copyright
BACKGROUND: To achieve delivery of a drug to tumors, folic acid (FA) was used as a targeting ligand to change nanocarriers. Since the folate receptor has more expression in several tumor types such as breast cancer. OBJECTIVES: The present study aimed to evaluate the effect of Doxorubicine-G2-FA (Do...
Gespeichert in:
Veröffentlicht in: | Iranian journal of veterinary medicine 2020-06, Vol.14 (2), p.147-158 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BACKGROUND: To achieve delivery of a drug to tumors, folic acid (FA) was used as a targeting ligand to change nanocarriers. Since the folate receptor has more expression in several tumor types such as breast cancer. OBJECTIVES: The present study aimed to evaluate the effect of Doxorubicine-G2-FA (Dox- G2-FA) with in vitro assays. The abbreviation of G2 represents the second generation of dendrimer synthesis. METHODS: For this purpose, Dox-G2-FA was synthesized and mass spectroscopy was used to confirm the synthesized component. Also, MTT assay, flow cytometry, and gene expression assay by real-time PCR were used to evaluate cell viability, apoptosis, and necrosis. RESULTS: In this study, the effect of Dox and Dox-G2-FA on the expression of Bax, Bcl2 genes showed that there was a significant decrease in the expression of the Bcl2 gene in the Dox-G2-FA group compared to Dox and control groups( P |
---|---|
ISSN: | 2251-8894 2252-0554 |
DOI: | 10.22059/ijvm.2019.291998.1005039 |